Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global CD47 (IAP) market was valued at USD 518.4 million in 2025 and is projected to reach USD 1.2 billion by 2034, exhibiting a CAGR of 9.8% during the forecast period. While the U.S. market accounted for approximately 38% of global revenue in 2025, China's market is expected to grow at a faster pace due to increasing oncology R&D investments.
CD47, also known as Integrin Associated Protein (IAP), is an immune checkpoint molecule that plays a crucial role in cancer immune evasion. This transmembrane protein delivers 'don't eat me' signals to macrophages, making it a promising target for cancer immunotherapy. The therapeutic landscape includes CD47 monoclonal antibodies, bispecific antibodies, and fusion proteins designed to block this immune inhibitory pathway.
The market growth is driven by rising incidence of hematologic malignancies and solid tumors, with the CD47 monoclonal antibody segment expected to dominate through 2034. Recent clinical advancements have accelerated development, exemplified by Gilead Sciences' acquisition of Forty Seven Inc. for USD 4.9 billion in 2020 to access its lead anti-CD47 candidate magrolimab. Other key players like Innovent Biologics and ALX Oncology are advancing their pipelines, with over 30 CD47-targeting therapies currently in clinical trials globally.
Growing Prevalence of Cancer and Immunotherapy Adoption
The CD47 (IAP) market is primarily driven by the rising global cancer burden, with over 19 million new cases diagnosed annually. CD47 inhibitors are gaining traction as a promising immunotherapy approach, particularly for hematologic malignancies and solid tumors. The increasing adoption of targeted therapies over conventional treatments is accelerating market growth.
Advancements in Clinical Pipeline
Over 15 CD47-targeting therapies are currently in clinical trials, with several in Phase II/III stages. The potential for combination therapies with checkpoint inhibitors like PD-1/PD-L1 drugs is creating significant interest from major pharmaceutical companies, with partnerships and licensing deals exceeding $2 billion in recent years.
The first FDA-approved CD47-targeting therapy could capture 35-40% of the immuno-oncology market within three years of launch
Investments in CD47 research have grown by 25% annually since 2020, reflecting strong confidence in this therapeutic approach.
MARKET CHALLENGES
Toxicity and Safety Concerns
CD47 inhibitors face challenges related to on-target toxicity, particularly anemia due to red blood cell targeting. Several clinical trials have been paused or modified due to adverse events, requiring complex dosing strategies and patient selection criteria.
Other Challenges
Regulatory Hurdles
The novel mechanism of action presents unique regulatory challenges, with agencies requiring extensive safety data before approval. Biomarker development for patient stratification remains a critical unmet need.
Commercialization Risks
With most agents still in clinical development, reimbursement pathways and market access strategies remain uncertain for CD47 therapies.
High Development Costs and Complexity
The average cost to develop a CD47 inhibitor through approval exceeds $900 million due to complex clinical trial designs and required safety monitoring. This creates substantial barriers for smaller biotech companies without pharmaceutical partnerships.
Expansion into New Oncology Indications
Emerging research suggests CD47's therapeutic potential beyond current targets, including myeloid malignancies and treatment-resistant solid tumors. The market could grow by $4.5 billion if successful in multiple myeloma and ovarian cancer applications.
Next-Generation CD47 Modulators
Second-generation agents with improved safety profiles and selective targeting mechanisms are entering clinical testing. These innovative approaches could expand the addressable patient population by 60% compared to first-generation inhibitors.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
CD47 Monoclonal Antibody dominates the market as the most clinically advanced therapeutic approach, with major pharmaceutical companies investing heavily in its development. The segment benefits from higher specificity in targeting CD47 receptors compared to other formats. Fusion proteins are emerging as promising alternatives due to their enhanced pharmacokinetic properties. |
| By Application |
|
Solid Tumor applications currently drive the market as CD47 inhibition shows significant potential in overcoming tumor immune evasion. Lymphoma treatments are gaining traction due to promising clinical trial results, while research is expanding into various hematological malignancies. The versatility of CD47-targeted therapies supports broad therapeutic applications across oncology. |
| By End User |
|
Hospital Pharmacies represent the primary distribution channel due to the need for specialized administration of CD47 therapies under medical supervision. Specialty clinics are increasingly adopting these treatments for targeted cancer therapies, while research institutes play a crucial role in developing next-generation CD47 inhibitors. The complex nature of these biologics favors controlled healthcare settings. |
| By Development Stage |
|
Clinical Trials dominate the current market landscape as most CD47-targeted therapies are in various phases of investigation. Approved therapies remain limited but are expected to grow significantly following recent breakthroughs. The robust preclinical pipeline indicates sustained long-term interest in CD47 as a therapeutic target, particularly in combination therapies. |
| By Therapeutic Approach |
|
Combination Therapy shows the most promise as CD47 inhibitors demonstrate synergistic effects with existing cancer treatments. Monotherapy approaches face challenges due to potential hematological toxicity, while bispecific antibodies represent an innovative approach to overcome resistance mechanisms. The market is shifting toward personalized combination regimens tailored to specific cancer types. |
The CD47 (IAP) Market is dominated by biopharmaceutical companies investing heavily in immuno-oncology research
The global CD47 (IAP) market is currently led by Gilead Sciences, which holds a significant market share through its innovative pipeline of immunotherapies. Following closely are Innovent Biologics and Akeso, Inc from China, demonstrating strong regional influence in the Asia-Pacific market. These companies operate in an oligopolistic structure where the top five players collectively control approximately % of global revenue.
Niche players like Arch Oncology and ImmuneOncia Therapeutics are making notable advancements in CD47 targeting therapies, particularly for hematologic malignancies. Several biotech firms including ALX Oncology and Surface Oncology are specializing in combination therapies that integrate CD47 inhibitors with existing treatments.
List of Key CD47 (IAP) Companies ProfiledZai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
TG Therapeutics
The global CD47 (IAP) market was valued at $XX million in 2025 and is projected to reach $XX million by 2034, growing at a CAGR of X.X% during the forecast period. This growth is driven by increasing R&D investments in cancer immunotherapy and the expanding pipeline of CD47-targeting therapies.
Other TrendsDominance of Monoclonal Antibody Segment
The CD47 Monoclonal Antibody segment is expected to reach $XX million by 2034, with a CAGR of X.X% in the next six years. This segment's dominance is attributed to its therapeutic efficacy in targeting solid tumors and lymphomas, with multiple candidates in late-stage clinical trials.
Regional Market DynamicsThe U.S. market is estimated at $XX million in 2025, while China is projected to reach $XX million. North America currently leads in market share due to advanced healthcare infrastructure, while Asia-Pacific shows the highest growth potential driven by expanding biopharma sectors in China, Japan, and South Korea.
Competitive Landscape
Key players including Gilead, Innovent Biologics, Akeso, Inc, and I-MAB accounted for approximately XX% of global revenue in 2025. Recent strategic collaborations and licensing agreements among these companies are accelerating clinical development and commercialization efforts.
Therapeutic Application TrendsSolid tumor applications currently dominate the market with XX% share in 2025, followed by lymphoma treatments. The development of combination therapies with PD-1/PD-L1 inhibitors is emerging as a key trend to overcome resistance mechanisms in cancer treatment.
Regional Analysis: CD47 (IAP) MarketEurope
Europe maintains strong CD47 (IAP) market presence with coordinated academic-industry networks across the UK, Germany, and Switzerland. The EMA's adaptive pathway approvals facilitate faster patient access to emerging CD47 therapies, while national healthcare systems support early technology adoption. Several EU-based biotechs focus on differentiated CD47 approaches like bispecific antibodies and next-generation targeting mechanisms. Strict pricing controls somewhat limit commercial potential compared to North America, though public-private partnerships compensate through shared R&D risk. The region demonstrates particular strength in hematology-focused applications of CD47 modulation.
Asia-Pacific
The Asia-Pacific CD47 market shows rapid expansion, led by China's growing biotech sector and Japan's established pharmaceutical companies. Chinese firms aggressively develop biosimilar versions of first-generation CD47 inhibitors while also investing in novel mechanisms. Australia serves as important clinical trial hub benefiting from streamlined ethics approvals. Regional dynamics feature both competition and collaboration, with multinational pharma establishing CD47 research centers in Singapore and South Korea to access regional talent pools and cost efficiencies in early-stage development.
South America
South America represents an emerging opportunity for CD47 therapies, though adoption faces healthcare infrastructure limitations outside major urban centers. Brazil leads regional clinical trial participation, particularly for blood cancer indications where unmet need remains high. Local manufacturers explore biosimilar pathways for approved CD47 drugs, while academic researchers focus on tropical disease applications potentially relevant to macrophage modulation mechanisms. Market growth depends heavily on pricing strategies and government health budget allocations for innovative cancer treatments.
Middle East & Africa
The MEA region shows nascent CD47 market development centered in Gulf Cooperation Council countries with expanding specialty care hospital networks. Limited local R&D capacity creates import dependency, though regional pharmaceutical companies express growing interest in licensing agreements. South Africa serves as clinical trial gateway for sub-Saharan Africa, particularly for HIV-associated lymphomas where CD47 targets may offer therapeutic advantages. Market penetration requires innovative access models addressing affordability constraints across most regional healthcare systems.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global CD47 (IAP) market was valued at USD 518.4 million in 2025 and is projected to reach USD 1.2 billion by 2034.
Which key companies operate in Global CD47 (IAP) Market?
-> Key players include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, and ImmuneOncia Therapeutics, among others.
-> Key growth drivers include rising incidence of hematologic malignancies and solid tumors.
-> U.S. accounted for approximately 38% of global revenue in 2025, while China is expected to grow at a faster pace.
-> Emerging trends include CD47 monoclonal antibodies, bispecific antibodies, and fusion proteins.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates